Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Long-term Debt
Borrowings due after more than one year.
Actuate Therapeutics IncNASDAQ: ACTU
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q1 FY2026 long-term debt was $404.99K, compared with $0 a year earlier. Over 3 fiscal years it compounded at +0.0% a year.
Context
- Long-term debt amounted to 4.5% of total assets at the end of Q1 FY2026, up 4.5 pp from a year earlier.
- Long-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 404.99K USD
- Year-over-year change
- —
- 3-year CAGR
- +0.0%
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 404.99K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 404.99K | — |
Long-term Debt vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
- Long-term debt amounts to 4.5% of total assets for ACTU, versus a peer median of 2.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $67.92M USD | — | — | 18.3% | |
| Mar 2026 | $13.35M USD | — | — | 8.5% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $9.48M USD | — | — | 41.8% |
| Mar 2026 | $8.29M USD | -12.4% | — | 3.5% | |
| Mar 2026 | $2.63M USD | — | — | 0.5% | |
| Mar 2026 | $507K USD | — | — | 0.9% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $404.99K USD | — | +0.0% | 4.5% |
| Mar 2026 | CHF 0 CHF | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ACTU) | — | -12.4% | — | 2.2% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.